

ASCIA 2013

**24th Annual Scientific Meeting of the Australasian
Society of Clinical Immunology and Allergy (ASCIA)
11-13 September 2013 • Perth Convention and
Exhibition Centre (PCEC) • Western Australia**

PROGRAM BOOK

Held in conjunction with:

- ASCIA 2013 Postgraduate Immunology Course – Tuesday 10 September 2013
- ASCIA 2013 Allergy and Immunology Update for nurses, dietitians and other health professionals – Saturday 14 September 2013
- ASCIA 2013 Immunopathology Update – Saturday 14 September 2013

ASCIA is the peak professional body of clinical immunology and allergy specialists in Australia and New Zealand and is a member society of the Asia Pacific Association of Allergy, Asthma and Clinical Immunology (APAAACI) and the World Allergy Organisation (WAO).

ascia

australasian society of clinical immunology and allergy inc.

www.allergy.org.au

Sponsors and Exhibitors

ASCIA gratefully acknowledges the generous support of the following sponsors:

Diamond Sponsors



CSL Behring



Gold Sponsors



Baxter



Exhibitors and other Sponsors

Sponsors and exhibitors confirmed at the time of publishing this program book are as follows:

- Abacus-ALS
- Abbott Nutrition
- Allergend
- Allergy & Anaphylaxis Australia
- Allergy New Zealand
- Alphapharm
- Asthma Australia
- AusEE
- AMSL/NZMS
- Baxter
- Bio-Strategy
- CSL Behring
- Diagnostic Solutions
- Ego Pharmaceuticals
- ESL Biosciences
- GlaxoSmithKline (GSK)
- HAE Australasia
- IDFA
- IDFNZ
- In Vitro Technologies
- Link
- Meda
- MedicAlert Foundation
- MSD
- National Asthma Council
- Neilmed
- Nestle Nutrition
- Novartis
- Nutricia Advanced Medical
- Nutricia Baby
- Octapharma
- Pathwest
- Shire
- Stallergenes
- Takeda
- TAMS
- ViroPharma

Note: The content of ASCIA 2013 is not influenced by its sponsors or exhibitors

WELCOME

CONTENTS

Sponsors and Exhibitors	1
Welcome	2
Secretariat	3
Program at a Glance	3
Program	4-9
Speakers and Chairs	10-12
Information (A-Z)	13-14
Clinical Grand Rounds: Program	21
Poster Abstracts: Index	22-24
Sponsor and Exhibitor Directory	25-32

On behalf of the Australasian Society of Clinical Immunology and Allergy (ASCIA) I warmly welcome you to Perth, Western Australia and to ASCIA 2013, the 24th Annual Scientific Meeting of the Australasian Society of Clinical Immunology and Allergy (ASCIA).

ASCIA is committed to providing excellence in continuing professional development for its members and other health professionals. In line with this commitment, ASCIA 2013 aims to provide an international standard of medical education in the areas of allergy and other immune diseases, including primary immunodeficiency and systemic autoimmune diseases.

I welcome you to ASCIA 2013 and trust that you will enjoy the fellowship of your ASCIA colleagues and all that Perth and Western Australia have to offer.

Clinical Associate Professor Richard Loh
ASCIA President

As Chair of the ASCIA 2013 organising committee, it is a great pleasure to welcome you to ASCIA 2013. The ASCIA 2013 Annual Scientific Meeting runs from Wednesday 11th to Friday 13th September and is being held in conjunction with:

- ASCIA Postgraduate Immunology Course on Tuesday 10th September.
- ASCIA 2013 Allergy and Immunology Update for nurses, dietitians and other health professionals on Saturday 14th September
- ASCIA 2013 Immunopathology Update on Saturday 14th September

The ASCIA 2013 scientific program will feature presentations by the following six keynote international speakers:

- Professor Abul Abbas (USA)
- Professor Raif Geha (USA)
- Dr Linda Cox (USA)
- Professor Ruby Pawankar (JAPAN)
- Professor Josep Dalmau (SPAIN, USA)
- Professor Harald Renz (GERMANY)

ASCIA 2013 also includes more than 40 other speakers and more than 40 Chairs from Australasia, including Professor Susan Prescott, who will present the 2013 Basten Oration.

A highlight of the ASCIA 2013 social program will be the Gala Dinner, to be held at the renowned State Reception Centre, part of Frasers Restaurant in Kings Park, with a spectacular view of Perth and the Swan River.

Situated beside the Swan River, Perth is like a living picture postcard, with outstanding views from Kings Park and Botanic Garden, one of the largest and most scenic inner city parks in the world. Perth is also Australia's sunniest capital city, where you can enjoy the beach, relax in natural bushland, sample world class local wines and watch an ocean sunset within 30 minutes of the city centre. We hope that you will have the opportunity to enjoy many of these attractions during your visit to Perth for ASCIA 2013.

Dr Richard Nolan
ASCIA 2013 Chair

On behalf of the ASCIA 2013 Organising Committee:

Dr John Bandouvakis, Dr Christine Bundell, Rachael Dunn, A/Prof Peter Hollingsworth, Monica Kemp, A/Prof Richard Loh, Dr Andrew McLean-Tooke, Val Noble, Prof Elizabeth Phillips, Ingrid Roche, Prof Susan Prescott, Sandra Vale.

Program at a Glance

Tuesday 10 Sept	Wednesday 11 Sept	Thursday 12 Sept	Friday 13 Sept	Saturday 14 Sept
PCEC Bellevue Ballroom 2	PCEC Bellevue Ballroom 2	PCEC Bellevue Ballroom 2	PCEC Bellevue Ballroom 2	PCEC Riverview Room 4 Meeting Rooms 1-3
Postgraduate Immunology Course	ASM Day 1	ASM Day 2	ASM Day 3	Immunopathology Update <i>run concurrently with</i> Allergy and Immunology Update
Registration	Registration JSAC Breakfast Forum	Breakfast Immune Deficiency	Breakfast Neuro-immunology	Registration
Introduction to the immune system; innate immunity and antigen presentation	Plenary - Origins of Allergy (Atopy)	Plenary - Origins of Allergy (Organ Specific Disease)	Plenary - Neuro-immunology	Session 1: see full program for details
Morning Tea	Morning Tea	Morning Tea	Morning Tea	Morning Tea
T lymphocyte activation and co-stimulation; Effector T cell subsets, Cytokines	Plenary - Immune Deficiency, Genes and Autoimmunity	Symposium - Anaphylaxis	Plenary - Asthma	Session 2: see full program for details
Lunch	Lunch	Lunch	Lunch	Lunch
B cells and antibodies; Immunological tolerance and immune regulation	Symposium - Immunotherapy	ASCIA AGM ASCIA Education Update WAO Update	Poster discussion session	Session 3: see full program for details
Afternoon Tea	Afternoon Tea	Afternoon Tea	Afternoon Tea	Afternoon Tea
Autoimmunity and immune mediated inflammatory diseases	Clinical Grand Rounds Presentations	Poster discussion session	Symposium - Drug Allergy	Session 4: see program for details
	Welcome Function PCEC Bellevue Ballroom Foyer	Gala Dinner PCEC Bellevue Ballroom Foyer	Closing Function PCEC Bellevue Ballroom Foyer	Wine and Cheese Foyer adjacent to PCEC Riverview Room 4

Secretariat



Registration and Abstract submission

GPO Box 3270 Sydney
NSW 2001
Phone: 02 9254 5000
Fax: 02 9251 3552

Email: registration@ascia2013.com.au
Website: www.ascia2013.com.au

Sponsorship, Exhibition and Program Inquiries



australasian society of clinical immunology and allergy inc.

PO Box 450 Balgowlah NSW 2093
Ph: 0425 216 402
Fax: 02 9907 9773
Email: education@allergy.org.au

Postgraduate Immunology Course

Tuesday 10 September 2013

Perth Convention and Exhibition Centre: Bellevue Ballroom 2

Course Director: Professor Abul Abbas	
07.30-08.30	Registration
08.30-09.00	Introduction to the Immune System
09.00-10.00	Innate Immunity, Antigen Presentation
10.00-10.30	Morning Tea
10.30-11.30	T Lymphocyte Activation and Co-stimulation
11.30-12.30	Effector T Cell Subsets, Cytokines
12.30-13.30	Lunch
13.30-14.30	B Cells and Antibodies
14.30-15.30	Immunological Tolerance and Immune Regulation
15.30-16.00	Afternoon Tea
16.00-17.00	Autoimmunity and Immune-Mediated Inflammatory Diseases
17.00-17.30	Discussion

This course on Basic Immunology, with emphasis on immunologic diseases and therapeutic strategies, has been developed as an education program of the Federation of Clinical Immunology Societies (FOCIS).

Day 1 Program

Wednesday 11 September 2013

Perth Convention and Exhibition Centre: Bellevue Ballroom 2

07.00-08.45	Registration	
07.15-08.45	Breakfast – JSAC forum for supervisors and trainees Chairs: Dr Tiffany Hughes, Dr Melanie Wong, Dr Miriam Hurst	
08.50-09.00	Welcome from ASCIA President and ASCIA 2013 Chair A/Prof Richard Loh, Dr Richard Nolan	
09.00-11.00	Plenary – Origins of Allergy (Atopy) Chairs: Prof Dianne Campbell, Prof Connie Katelaris	
09.00-09.30	Basten Oration: Allergy and the NCD pandemic; the canary in the coal mine	Prof Susan Prescott
09.30-10.00	Progress on the new frontier: epigenetics and allergy	Dr David Martino
10.00-10.30	New lessons from the microbial world	Prof Harald Renz
10.30-11.00	Nutrition, diet and feeding practices in the origins of allergic disease	A/Prof Debra Palmer
11.00-11.30	Morning Tea	
11.30-13.00	Plenary – Immune Deficiency, Genes and Autoimmunity Chairs: Dr Shannon Brothers, Dr Melanie Wong	
11.30-12.00	Approaches to the discovery of novel immunodeficiencies	Prof Raif Geha
12.00-12.30	Balancing tolerance and autoimmunity: strategies for controlling harmful immune responses	Prof Abul Abbas
12.30-13.00	Genetic testing for PID – what is available in Australasia	A/Prof Richard Loh
13.00-14.00	Lunch	
14.00-15.30	Symposium – Immunotherapy Chairs: Dr John Bandouvakis, Dr William Smith	
14.00-14.45	Immune mechanisms of tolerance in SLIT and SCIT and differences	Dr Linda Cox
14.45-15.30	Venom immunotherapy... established cure or work in progress?	Prof Simon Brown
15.30-16.00	Afternoon Tea	
16.00-18.00	Clinical Grand Rounds Presentations – presented by Advanced Trainees 8 minutes have been allocated to each presentation and discussion of 15 cases: Refer to page 21 for program Chairs: Dr Michael O’Sullivan, Prof Pete Smith	
18.00-19.00	Welcome Function Perth Convention and Exhibition Centre: Bellevue Ballroom Foyer	

Day 2 Program

ASCIA 2013

Thursday 12 September 2013

Perth Convention and Exhibition Centre: Bellevue Ballroom 2

07.00-08.45	Registration	
07.00-08.45	Breakfast – Immune Deficiency	
	Chairs: Dr Andrew Mclean-Tooke, Dr Jane Peake	
07.15-07.45	Predicting adverse events following immune intervention	A/Prof Sean Riminton
07.45-08.15	Monitoring of CVID and patients with humoral immune deficiency	Dr Andrew Mclean-Tooke
08.15-08.45	Discussion of PID cases (3)	Prof Raif Geha
09.00-11.00	Plenary – Origins of Allergy (organ specific disease)	
	Chairs: Dr Richard Nolan, Prof Susan Prescott	
09.00-09.30	Role of skin and mucosal barrier integrity in origins of allergic disease: preventive strategies	Prof Katie Allen
09.30-10.00	Systems biology approaches to allergy and asthma pathogenesis	Dr Anthony Bosco
10.00-10.30	Epithelia – immune cell interactions in airways inflammation: therapeutic targets	Prof Ruby Pawankar
10.30-11.00	Progress with food allergy – experience with oral immunotherapy in practice	A/Prof Mimi Tang
11.00-11.30	Morning Tea	
11.30-12.30	Symposium – Anaphylaxis	
	Chairs: Dr Miriam Hurst, Dr Preeti Joshi	
11.30-12.00	New insights into pathogenesis of anaphylaxis	Dr Shelley Stone
12.00-12.30	Anaphylaxis - unusual presentation and causes	Dr Ray Mullins
12.30-13.30	Lunch	
13.30-14.30	ASCIA AGM	
	Chair: A/Prof Richard Loh	
14.30-15.00	ASCIA Education Update	
	Chair: Dr Sara Barnes	Dr Sam Mehr Dr William Smith
15.00-15.30	Allergy – a major Global Health Issue: World Allergy Organisation (WAO) White Book	
	Chair: Prof Susan Prescott	Prof Ruby Pawankar
15.30-16.00	Afternoon Tea	
16.00-17.30	Poster Discussion Session	
	10 minutes have been allocated to each presentation and discussion of 9 pre-selected posters	
	Chairs: Prof Martyn French, Dr Patrick Quinn	
18.30-22.30	Gala Dinner	
	State Reception Centre, Frasers Restaurant, Kings Park	
	Buses depart from 18.00-18.30 from PCEC	

Day 3 Program

Friday 13 September 2013

Perth Convention and Exhibition Centre: Bellevue Ballroom 2

07.00-08.30	Registration	
07.00-08.30	Breakfast - Neuroimmunology Chairs: A/Prof Peter Hollingsworth, A/Prof Allan Kermode Case presentations	Prof Josep Dalmau
08.45-10.30	Plenary - Neuroimmunology Chairs: A/Prof Peter Hollingsworth, A/Prof Sean Riminton	
08.45-09.30	Syndromes and synaptic mechanisms of autoimmune encephalitis	Prof Josep Dalmau
09.30-10.00	Multiple sclerosis - controversies	A/Prof Allan Kermode
10.00-10.30	Gene and environment interactions in multiple sclerosis	Dr David Nolan
10.30-11.00	Morning Tea	
11.00-12.30	Plenary - Asthma Chairs: Dr Colin Somerville, Dr Celia Zubrinich	
11.00-11.45	Inflammatory and non-inflammatory pathways in asthma – from bench to bedside	Prof Harald Renz
11.45-12.30	Asthma and immunotherapy	Dr Linda Cox
12.30-13.30	Lunch	
13.30-15.00	Poster Discussion Session 10 minutes have been allocated to each presentation and discussion of 9 pre-selected posters Chairs: A/Prof Bob Heddle, Dr Peter Richmond	
15.00-15.30	Afternoon Tea	
15.30-17.00	Symposium - Drug Allergy Chairs: Dr Jeremy McComish, Dr Robert Pye	
15.30-16.00	Patch testing to drugs	Prof Elizabeth Phillips
16.00-16.30	Beta-lactam testing: can we make it more effective?	Dr Jack Bourke
16.30-17.00	Adverse reactions to anti-inflammatories	Dr William Smith
17.00-18.00	Closing Function / Wine and Cheese including CGR and Poster awards Perth Convention and Exhibition Centre: Bellevue Ballroom Foyer	
19.00	Concurrent dinners including: Trainee and Consultants Dinner supported by CSL Behring, Parmelia Hilton Hotel Perth Nurses Dinner supported by Stallergenes, Parmelia Hilton Hotel Perth	

ASCIJA 2013 Immunopathology Update

Saturday 14 September 2013

Perth Convention and Exhibition Centre: Riverview Room 4

08.00–08.25	Registration	
08.25–08.30	Welcome and Introduction Dr Christine Bundell, Monica Kemp	
08.30–10.30	Session 1 Chairs: Dr Anna Brusch, Dr Christine Bundell	
08.30–09.15	Laboratory aspects of neuronal immunology	Prof Josep Dalmau
09.15–09.35	Case study: Anti NMDA R	Dr Ben McGettigan
09.35–10.00	In vivo and in vitro testing for penicillin allergy	Dr Jack Bourke
10.00–10.30	Immunopathology poster presentations (3)	
10.30–11.00	Morning Tea	
11.00–12.30	Session 2 Chairs: Dr Meilyn Hew, Dr Melanie Wong	
11.00–11.45	Post-natal development of the human innate immune system	Dr Andrew Currie
11.45–12.15	Laboratory assessment of adult primary immune deficiency	A/Prof David Fulcher
12.15–12.30	Case study	Dr Eliska Furlong
12.30–13.30	Lunch	
13.30–15.00	Session 3 Panel: Dr Theo de Malmanche, Dr Tiffany Hughes, Gerhard Saueracker	
13.30–14.30	Review of IIF slides (cytoplasmic including myositis on Hep2000 and LKS)	
14.30–15.00	Isotype diversification of antibody responses and the role of follicular helper T cells Chair: Dr Michael O'Sullivan	Prof Martyn French
15.00–15.30	Afternoon Tea	
15.30–17.00	Session 4 Chairs: Mark Goulding, Dr Miriam Hurst	
15.30–16.00	Clinical utility of testing for Th17 T cells	Adj A/Prof Michaela Lucas
16.00–16.20	Complement overview	A/Prof Peter Hollingsworth
16.20–16.40	Mannose binding lectin overview	Monica Kemp
16.40–17.00	C4 gene copy number	A/Prof Campbell Witt
17.00–18.00	Wine and Cheese Perth Convention and Exhibition Centre: Foyer adjacent to Riverview Room 4	

Allergy and Immunology Update

Saturday 14 September 2013

Perth Convention and Exhibition Centre: Meeting Rooms 1-3

08.00–08.45	Registration	
08.50–11.00	Session 1: Meeting Rooms 1-2 Chairs: Rachael Dunn, Ingrid Roche	
08.50-09.00	Welcome and Introduction Rachael Dunn, Ingrid Roche	
09.00–09.45	Gastrointestinal allergic disorders	Prof Katie Allen
09.45-10.30	Specific oral tolerance induction (SOTI)	A/Prof Mimi Tang
10.30-11.00	Morning Tea	
11.00-12.30	Session 2: Meeting Rooms 1-2 Chairs: Val Noble, Barbara Dennison	
11.00-11.45	Management of food and needle phobias	Jo Elliot
11.45-12.30	Management of anaphylaxis in teenagers and young adults	Dr Adelaide Withers
12.30-13.30	Lunch	
13.30-15.00	Session 3 - Concurrent Program A: Meeting Rooms 1-2 Chairs: Vicki O'Brien, Sacha Palmer	
13.30-14.15	Primary immune deficiencies overview	Dr Melanie Wong
14.15-15.00	Update on SCIg and HAE <i>This session is supported by an unrestricted educational grant from ViroPharma.</i>	Rachael Dunn
13.30-15.00	Session 3 - Concurrent Program B: Meeting Room 3 Chairs: Paula Brown, Evania Marlow	
13.30-14.15	Food allergy research update	A/Prof Debra Palmer
14.15-15.00	Dietitians toolbox: practicalities of managing clients with food allergy	Merryn Netting Anna Richards Vicki McWilliam
15.00-15.30	Afternoon Tea	
15.30-16.30	Poster Discussion Session: Meeting Rooms 1-2 Chairs: Pamela Burton, Kathy Beck	
16.30-17.30	Subcommittee Meeting – ASCIA Nurses: Meeting Rooms 1-2 Chair: Rachael Dunn	
16.30-17.30	Subcommittee Meeting – ASCIA Dietitians: Meeting Room 3 Chair: Ingrid Roche	
17.00-18.00	Wine and Cheese Perth Convention and Exhibition Centre: Foyer adjacent to Riverview Room 4	

International Keynote Speakers



Professor Abul Abbas MBBS

President, Federation of Clinical Immunology Societies (FOCIS)

Professor and Chair, Department of Pathology, University of California, San Francisco (UCSF), USA

Professor Abbas completed his medical qualifications in New Delhi, India, before moving to the USA in 1970.

As well as being the current President of the Federation of Clinical Immunology Societies (FOCIS) Professor Abbas:

- continues to have an extensive commitment to training and fellowship programs
- has received over 20 awards/honours
- has been a representative on over 40 committees
- has authored or co-authored more than 175 publications and 4 medical textbooks
- is the co-editor of Annual Reviews of Pathology

Professor Abbas's research is focused on immunological tolerance and autoimmunity. His laboratory is exploring the mechanisms that maintain tolerance to tissue and systemic self-antigens, and conditions that lead to the breakdown of self-tolerance and the development of autoimmunity. His laboratory is also analysing the roles of different cytokines and T-cell subsets in autoimmune disease, and in the function of regulatory T-cells.

At ASCIA 2013 Professor Abbas will be presenting as follows:

1. **Postgraduate Immunology Course** on Tuesday 10 September, 08.30-17.30
2. **Balancing tolerance and autoimmunity: strategies for controlling harmful immune responses** on Wednesday 11 September, 12.00-12.30

Professor Abbas's travel for ASCIA 2013 is supported by an educational grant from PathWest.



Dr Linda Cox MD FAAAAI FAAAAI FACP

President, American Academy of Allergy, Asthma and Immunology (AAAAI)

Consultant, Allergy and Asthma Center, Fort Lauderdale, Florida USA

Assistant Clinical Professor of Medicine, University of Miami School of Medicine

Dr Cox completed her medical qualifications in 1985 at the Northwestern University School of Medicine, Chicago, Illinois. This was followed by post graduate training in Allergy and Immunology at National Jewish Hospital, Denver, Colorado and Internal Medicine at University of Miami, Jackson Memorial Hospital, Miami, Florida.

As well as being the current President of the American Academy of Allergy, Asthma and Immunology (AAAAI), Dr Cox:

- has worked in private practice (solo) since 1992
- has received over 20 awards/honours
- is widely published in the field of allergy, asthma and immunology, particularly in the area of allergen immunotherapy
- is a current and past member of the several medical organisations Board of Directors and committees

Dr Cox's research interests include sublingual immunotherapy safety and efficacy, comparative effectiveness of allergen immunotherapy and immunotherapy adherence

At ASCIA 2013 Dr Cox will be presenting as follows:

1. **Immune mechanisms of tolerance in SLIT and SCIT and differences** on Wednesday 11 September, 14.00-14.45
2. **Asthma and immunotherapy** on Friday 13 September, 11.45-12.30

Dr Cox's travel for ASCIA 2013 is supported by an unrestricted educational grant from Stallergenes.



Professor Josep Dalmau MD PhD

Research Professor ICREA-IDIBAPS, Neurology, Hospital Clínic, Barcelona, Spain

Adjunct Professor of Neurology, University of Pennsylvania, Philadelphia, PA, USA

Professor Dalmau completed his medical education at the Autònoma University of Barcelona, Spain, gaining MD Hons in 1977 and PhD (Hons) in 1993. His postgraduate training in Neurology and Neuro-oncology was undertaken in Barcelona, Spain (University de la Sta. Cruz y San Pablo) and New York, USA (Cotzias Laboratory of Neuro-Oncology, Sloan Kettering Institute; New York Hospital, Cornell University; Memorial Hospital for Cancer and Allied Diseases).

As well as being a research Professor in Barcelona, he is also an associate investigator, Abramson Comprehensive Cancer Research at the University of Pennsylvania, USA.

Professor Dalmau is widely published in the field of neuro-oncology and neuronal immunology, particularly in the area of autoimmune encephalitis and his research has led to important discoveries in this area.

At ASCIA 2013 Professor Dalmau will be presenting as follows:

1. **Neuroimmunology case presentations (breakfast session)** on Friday 13 September, 07.00-08.30
2. **Syndromes and synaptic mechanisms of autoimmune encephalitis** on Friday 13 September, 08.45-09.30

International Keynote Speakers

3. **Laboratory aspects of neuronal immunology** on Saturday 14 September, 08.30-09.15

Professor Dalmau's travel for ASCIA 2013 is supported by unrestricted educational grants from CSL Behring (Annual Scientific Meeting) and ESL Biosciences (Immunopathology Update).



Professor Raif Geha MD

Chief, Division of Immunology, Boston Children's Hospital, Boston MA, USA

Raif S. Geha, received his M.D. degree in 1969 from the American University of Beirut, Lebanon, and trained in Pediatrics and Immunology at Boston Children's Hospital and Harvard Medical School. He is the James Gamble Professor of Pediatrics, Harvard Medical School and the Chief of the Division of Immunology, Allergy, Rheumatology and Dermatology Division at Boston Children's Hospital. Dr. Geha's research interests are in molecular and cellular mechanisms of primary immunodeficiencies and atopic dermatitis. Dr. Geha has received the Mead Johnson Award for Pediatric Research, the Kuwait Foundation for the Advancement of Sciences Prize, and the American Association of Immunologists Prize in Human Immunology Research. He is a member of the American Society of Clinical Investigation and has chaired the IUIS Committee on Immunodeficiency and the Clinical Immunology Society. He has contributed to date more than 365 original articles. His publications have appeared in *Cell*, *Immunity*, *Nature*, *Nature Immunology*, *Molecular Cell*, *PNAS*, *Journal of Experimental Medicine*, *Journal of Clinical Investigation*, *Journal of Immunology* and *Journal of Allergy and Clinical Immunology*. Dr. Geha has trained more than 120 postdoctoral fellows, many of whom are leaders in the fields of Allergy and Immunology.

At ASCIA 2013 Professor Geha will be presenting as follows:

1. **Approaches to the discovery of novel immunodeficiencies** on Wednesday 11 September, 11.30-12.00
2. **Discussion of PID cases (breakfast session)** on Thursday 12 September, 08.15-08.45

Professor Geha's travel for ASCIA 2013 is supported by an unrestricted educational grant from CSL Behring.



Professor Ruby Pawankar MD PhD FAAAAI

President, World Allergy Organisation (WAO)
Professor, Allergy and Rhinology, Nippon Medical School, Tokyo, Japan

Professor Ruby Pawankar completed her undergraduate medical education at the Armed Forces Medical College in Pune, India, post graduated at the BJ Medical College,

Pune and then trained in allergy and clinical immunology at Nippon Medical School and Juntendo University School of Medicine, in Tokyo Japan. She received her doctorate in allergy and clinical immunology from Nippon Medical School, where she is currently a Professor. She is also a Guest Professor at Showa University School of Medicine, Tokyo, Japan and Kyung Hee University School of Medicine, Seoul, Korea.

In addition to being the current President of the World Allergy Organization, Professor Pawankar:

- is widely published in the field of allergy, asthma and clinical immunology
- is an editor of several peer reviewed journals and books
- is a Member/Fellow of several allergy, asthma and clinical immunology societies serving also on their committees and boards
- has delivered several named lectures nationally and internationally
- has mentored several Japanese and international fellows in allergy and clinical immunology
- has received several national and international awards, including the Pravasi Bharatiya Samman (Overseas Indian Award), presented to her in 2010 by the President of India.

At ASCIA 2013 Professor Pawankar will be presenting as follows:

1. **Epithelia – immune cell interactions in airways inflammation: therapeutic targets** on Thursday 12 September, 10.00-10.30
2. **Allergy – a major Global Health Issue: World Allergy Organisation (WAO) White Book** on Thursday 12 September, 15.00-15.30



Professor Harald Renz MD

President, German Society of Allergy and Clinical Immunology

Professor of Laboratory Medicine, Philipps-University of Marburg, Germany

Specialist in Clinical Immunology and Allergology

Head, Department of Laboratory Medicine and Molecular Diagnostics, University Hospital Marburg, Germany

Professor Harald Renz completed his subspecialty training in Clinical Immunology and Allergology (1988-1995) in Marburg, Denver and Berlin.

His work on disease-related animal models has led to the development of mouse models for various disease-related phenotypes, including acute and chronic airway inflammation, airway remodelling, perinatal immune-development. He has further developed the concept of neuro-immune interaction in bronchial asthma and atopic dermatitis and is currently involved in the translation of the hygiene hypothesis from epidemiology to mechanism. He has published more than 200 original articles in peer-reviewed international journals, has contributed with 87 review articles and editorials and has edited 44 book chapters.

Professor Renz is the current President of the German Society of Allergology and Clinical Immunology. He also participates as an active member in several international scientific societies including AAAAI, EAACI and the ERS.

At ASCIA 2013 Professor Renz will be presenting as follows:

1. **New lessons from the microbial world** on Wednesday 11 September, 10.00-10.30

2. **Inflammatory and non-inflammatory pathways in asthma from bench to bedside** on Friday 13 September, 11.00-11.45

ASCIA 2013 Basten Oration



Professor Susan Prescott MBBS BMedSc FRACP PhD

Winthrop Professor, School of Paediatrics and Child Health, University of Western Australia

Specialist Allergy and Immunology physician, Princess Margaret Hospital, Perth, Western Australia

Professor Susan Prescott's contributions to research in the area of allergy and early immune development have been translated into novel concepts and led to a paradigm shift in the pathogenesis of allergic disease.

She is widely published (as an author or co-author of more than 200 scientific publications) and has been awarded eight fellowships including a Winston Churchill award. She is also an author of two recently published books "The Allergy Epidemic: A mystery of modern life" and "The Calling: A true story of faith, hope and love" based on her grandmother's pioneering medical footsteps.

Professor Prescott has been an ASCIA member since 1996 and is a regular presenter and chair at ASCIA Annual Scientific Meetings. She is actively involved in the ASCIA Paediatric committee, contributing to the development of several ASCIA educational resources, particularly in the areas of allergy prevention and infant feeding advice. She is also a member of the World Allergy Organisation (WAO) Board of Directors and regularly presents at International conferences.

At ASCIA 2013 Professor Prescott will be presenting as follows:

1. **Basten Oration: Allergy and the NCD Pandemic; the Canary in the Coal Mine** on Wednesday 11 September, 09.00-09.30

Other Invited Speakers

- Prof Katie Allen VIC
- Dr Anthony Bosco WA
- Dr Jack Bourke WA
- Prof Simon Brown WA
- Dr Andrew Currie WA
- Dr Theo de Malmanche NSW
- Ms Rachael Dunn WA
- Ms Jo Elliot WA
- Prof Martyn French WA
- A/Prof David Fulcher NSW
- Dr Eliska Furlong WA
- A/Prof Peter Hollingsworth WA
- Dr Tiffany Hughes SA
- Ms Monica Kemp WA
- A/Prof Allan Kermode WA
- A/Prof Richard Loh WA
- Adj A/Prof Michaela Lucas WA
- Dr David Martino VIC
- Dr Benjamin McGettigan WA, NZ
- Dr Andrew McLean-Tooke WA
- Ms Vicki McWilliam VIC
- Dr Sam Mehr NSW
- Dr Raymond Mullins ACT
- Ms Merryn Netting SA
- Dr David Nolan WA
- A/Prof Debra Palmer WA
- Prof Elizabeth Phillips WA
- Ms Anna Richards NZ
- A/Prof Sean Riminton NSW
- Mr Gerhard Saueracker WA
- Dr William Smith SA
- Dr Shelley Stone WA
- A/Prof Mimi Tang VIC
- Dr Adelaide Withers WA
- A/Prof Campbell Witt WA
- Dr Melanie Wong NSW

Chairs

- Dr John Bandouvakis WA
- Dr Sara Barnes VIC
- Ms Kathy Beck QLD
- Dr Shannon Brothers NZ
- Ms Paula Brown QLD
- Dr Anna Bruschi WA
- Dr Christine Bundell WA
- Ms Pamela Burton NSW
- Prof Dianne Campbell NSW
- Ms Barbara Dennison NSW
- Ms Rachael Dunn WA
- Prof Martyn French WA
- Mr Mark Goulding WA
- A/Prof Bob Heddle SA
- Dr Meilyn Hew WA
- A/Prof Peter Hollingsworth WA
- Dr Tiffany Hughes SA
- Dr Miriam Hurst NZ
- Dr Preeti Joshi NSW
- Prof Connie Katelaris NSW
- A/Prof Allan Kermode WA
- A/Prof Richard Loh WA
- Ms Evania Marlow WA
- Dr Jeremy McComish VIC
- Dr Andrew McLean-Tooke WA
- Ms Valerie Noble WA
- Dr Richard Nolan WA
- Ms Vicki O'Brien WA
- Dr Michael O'Sullivan WA
- Ms Sacha Palmer SA
- Dr Jane Peake QLD
- Prof Susan Prescott WA
- Dr Robert Puy VIC
- Dr Patrick Quinn SA
- Dr Peter Richmond WA
- A/Prof Sean Riminton NSW
- Ms Ingrid Roche WA
- Prof Pete Smith QLD
- Dr William Smith SA
- Dr Colin Somerville WA
- Dr Melanie Wong NSW
- Dr Celia Zubrinich VIC

Information (A-Z)

Abstracts

Poster and Clinical Grand Rounds abstracts listed in this book have been published online in the **Internal Medicine Journal (IMJ) in September 2013.**

Refer to the ASCIA website: www.allergy.org.au/health-professionals/meetings/ascia-annual-scientific-meetings/published-abstracts-ascia

Accommodation

Contact details for the main Perth hotels booked by ASCIA 2013 delegates are as follows:

Adina Apartment Hotel

Address: 33 Mounts Bay Road, Perth (next to the Perth Convention and Exhibition Centre)

Website: www.adinahotels.com.au/adina-apartment-hotel-perth/hotel

Email: perth@adinahotels.com.au

Phone: 08 9217 8000

Rydges Hotel Perth

Address: 815 Hay Street, Perth (corner King Street) - approximately 10 minutes walk from PCEC

Website: www.rydges.com/accommodation/western-australia/perth-cbd/

Email: reservations_perth@rydges.com

Phone: 08 9263 1800

Mounts Bay Waters Apartments

Address: 112 Mounts Bay Road, Perth - approximately 10 minutes walk from PCEC

Website: www.mounts-bay.com.au/

Email: perth@waldorf.com.au

Phone: 1800 241 343

For information about other Perth hotels visit:

www.westernaustralia.com/au/Search/Pages/Search.aspx?r=1&pretty=experience_perth/Accommodation

Attendance Certificates

Certificates of attendance are included in the registration envelope, together with a receipt for the registration payment.

Attractions

- **Kings Park and Botanic Garden**, one of the largest and most scenic inner city parks in the world and a short (but steep) walk from the Perth Convention and Exhibition Centre: www.bgpa.wa.gov.au/kings-park
- **Riverside walking and cycling track** from Perth to Crawley, which passes by the historical Old Swan Brewery Bar and Restaurant. www.theoldbrewery.com.au/
- **Cottesloe Beach**, about 30 minutes drive from Perth and you can watch a spectacular sunset over the Indian Ocean: www.westernaustralia.com/en/Things_to_See_and_Do/Sun_Surf_and_Sea_Life/Pages/Perth_Beaches.aspx
- **Fremantle** is a further 15 minutes drive from Cottesloe, and is a historical port city with an excellent waterfront Maritime Museum and a range of other historical and cultural attractions. www.fremantlewesternaustralia.com/
- **Rottneest Island** – this can be visited in a day by catching a ferry from Perth or Fremantle: www.rottneestisland.com/
- **Swan Valley** is famous for its food and wine and is located just 25 minutes from the Perth city centre - wine cruises on the Swan river are a popular way to explore this region: www.swanvalley.com.au
- **Margaret River region** is famous for its wines and beaches, and is a 3-4 hour drive south from Perth: www.margaretriver.com/regions/
- **Western Australian wildflowers** are renowned as being one of the most spectacular wildflower displays in the world from June to November: www.westernaustralia.com/en/Things_to_See_and_Do/Forest_and_Flowers/WAWildflowers/Pages/WAWildflowers.aspx
- **For general information about Western Australia** visit www.westernaustralia.com

Awards and Travel Scholarships

- Clinical Grand Rounds Prize/s for advanced trainees (\$2,500) supported by **Stallergenes**
- Food Allergy Poster Prize (\$1,000) supported by **Nestlé Nutrition**
- Immunopathology Poster Prize (\$1,000) supported by **Abacus ALS**
- NAC Asthma Poster Prize (\$1,000) supported by the **National Asthma Council (NAC)**
- Nurses Poster Prize/s (\$2,500) supported by **Stallergenes**
- Paul Clarke Allergy Poster Prize (\$1,000) supported by **ASCIA**
- PID Poster or Presentation Prize (\$1,000) supported by **CSL Behring**

A total of twenty ASCIA 2013 Travel Scholarships for Advanced Trainees of \$500 each have been awarded and these are supported by educational grants of \$2,500 each from **Abacus-ALS, ASCIA, CSL Behring** and **Stallergenes**.

Breakfast Sessions

Breakfast sessions are included in the ASCIA 2013 ASM registration fee. For catering purposes delegates must RSVP when they register for ASCIA 2013.

Disclaimers

In the event of industrial disruption or a natural disaster the meeting organisers cannot be held responsible for any losses incurred by delegates. The program is correct at the time of printing; however the organisers reserve the right to alter the program if necessary.

Dress Code

The dress code is smart casual throughout the meeting and cocktail for the Gala Dinner.

Exhibition

We encourage delegates to visit the ASCIA 2013 exhibition stands throughout the meeting which is located in the Perth Convention and Exhibition Centre in Bellevue Ballroom 1 from Wednesday 11th to Friday 13th September and in the Foyer adjacent to Riverview Room 4 on Saturday 14th September 2013. Lunches and tea breaks will be served in these exhibition areas.

Secretariat

Registration and Abstract submission

ICMS Australasia Pty Ltd

GPO Box 3270 Sydney

NSW 2001

Phone: 02 9254 5000

Fax: 02 9251 3552

Email: registration@ascia2013.com.au

Website: www.ascia2013.com.au

Sponsorship, Exhibition and Program Inquiries

ASCIA Executive Officer

PO Box 450 Balgowlah

NSW Australia 2093

Ph: 0425 216 402

Fax: 02 9907 9773

Email: education@allergy.org.au

Website: www.ascia2013.com.au

Smoke Free Policy

It is the policy that the ASCIA 2013 meeting area of the venue and all related social functions are smoke-free.

Social Program

ASCIA 2013 Welcome Function

Wednesday 11 September, 18.00 to 19.00

Perth Convention and Exhibition Centre: Bellevue Ballroom Foyer

ASCIA 2013 Gala Dinner

Thursday 12 September, 18.30 to 22.30

State Reception Centre, Frasers Restaurant, Kings Park

ASCIA 2013 Closing Function / Wine and Cheese including CGR and Poster awards

Friday 13 September, 17.00-18.00

Perth Convention and Exhibition Centre: Bellevue Ballroom Foyer

Concurrent sponsored dinners

Friday 13 September, 19.00, including:

Trainee and Consultants Dinner supported by CSL Behring, Parmelia Hilton Hotel Perth

Nurses Dinner supported by Stallergenes, Parmelia Hilton Hotel Perth

Wine and Cheese: ASCIA 2013 Immunopathology Update; ASCIA 2013 Allergy and Immunology Update

Saturday 14 September, 17.00-18.00

Perth Convention and Exhibition Centre: Foyer adjacent to Riverview Room 4

Special Requirements

Please provide details of any special diet, special needs or disability assistance required when you register.

Travel

Perth is regularly accessed by flights from capital cities in Australia and New Zealand. Perth Airport is around 30 minutes drive to the Perth City Centre, where the Perth Convention and Exhibition Centre is located. Transport options to and from the Airport include taxis or airport buses.

Which of your patients is at risk of anaphylaxis? Help them be prepared with 2x EpiPen® Adrenaline Auto-Injectors¹⁻³



My tongue
feels strange
when I eat eggs⁴



EPIPEN® EPIPEN® Jr
(Adrenaline) Auto-Injectors 0.3/0.15mg

Nothing else is an EPIPEN®

PBS Information: Authority Required. Refer to PBS Schedule for full authority information.

BEFORE PRESCRIBING, PLEASE REVIEW APPROVED PRODUCT INFORMATION
AVAILABLE ON REQUEST FROM ALPHAPHARM.

MINIMUM PRODUCT INFORMATION EpiPen® Adrenaline Auto-Injector 0.3mg / 0.3mL EpiPen® Jr. Adrenaline Auto-Injector 0.15mg/0.3mL. The following are not a complete listing: **Indication:** For the emergency treatment of anaphylaxis (acute severe allergic reaction) due to insect stings or bites, foods, drugs or other allergens. **Contraindications:** Contraindications are relative, as this product is intended for use in life-threatening emergencies. Certain arrhythmias, cerebral arteriosclerosis, vasopressor drug contraindication, shock (except anaphylactic shock), certain types of general anaesthesia. **Precautions:** Sulfite allergy, intravenous administration, ventricular fibrillation, prebrillatory rhythm, tachycardia, myocardial infarction, cardiovascular disease, organic heart disease, cardiac dilation, cerebral arteriosclerosis, prostatic hypertrophy, elderly, individuals with diabetes, hypertension, narrow angle glaucoma, hyperthyroidism, organic brain damage, psychoneurosis, phenothiazine-induced circulatory collapse, Parkinsonism. Avoid injection into hands, feet, ears, nose, buttocks, genitalia. Use in Pregnancy: Pregnancy Category A. Excreted in breast milk. Use with caution when maternal blood pressure is in excess of 130/80. Interactions: CNS medicines, alpha and beta adrenergic blockers, some general anaesthetics, hypoglycaemic agents. **Adverse Effects:** Anxiety, restlessness, tachycardia, respiratory difficulty, tremor, weakness, dizziness, headache, dyspnoea, cold extremities, pallor, sweating, nausea, vomiting, sleeplessness, hallucinations, flushing of face and skin. Psychomotor agitation, disorientation, impaired memory, potentially fatal ventricular arrhythmias, severe hypertension which may lead to cerebral haemorrhage and pulmonary oedema. Angina may occur in patients with CAD. **Dosage:** Single intramuscular injection into anterolateral aspect of thigh, repeat as directed if symptoms recur or have not subsided. Adults >30kg: EpiPen® Auto-Injector (0.3mg adrenaline) Children 15–30kg: EpiPen® Jr. Auto-Injector (0.15mg adrenaline). The prescribing physician may choose to prescribe more or less than this amount; please refer to relevant guidelines.

Reference: 1. Burks WA *et al.* *J Allergy Clin Immunol* 2012;129:906–920. 2. ASCIA: Guidelines for EpiPen® Prescription 2012. 3. Pharmaceutical Benefits Schedule Accessed December 2012. 4. Simons *et al.* *WAO Journal* 2011; 4:13–37. Alphapharm Pty. Limited. ABN 93 002 359 739, Level 1, 30 The Bond, 30–34 Hickson Road, Millers Point, NSW, 2000. Medical Information Phone: 1800 028 365, www.alphapharm.com.au ALP0432 inCeptiv July 2013

NESTLÉ | OFFERING THE COMPLETE ALLERGY SOLUTION

FROM RISK REDUCTION TO MANAGEMENT IN FORMULA FED INFANTS



GENERAL PURPOSE
FORMULA FOR HEALTHY
TERM INFANTS

RISK REDUCTION



NAN® H.A. 1 Gold

The **only clinically proven** H.A. starter infant formula shown to **reduce allergy risk by up to 50%** in high-risk formula fed infants.^{†1,2}

† Compared to intact cow's milk formula


NOT SUITABLE FOR GENERAL USE AND SHOULD BE USED
UNDER MEDICAL SUPERVISION

MANAGEMENT



ALFARÉ®

Australian & International Guidelines recommend an extensively hydrolysed formula such as **ALFARÉ® as the 1st choice in treating cow's milk allergy** in infants under 6 months of age.^{3,4,5}



ALFAMINO® COMING SOON*

Introducing the latest development in hypoallergenic elemental formulas **for the nutritional management of severe & complicated cases of Cow's Milk Protein Allergy & Food Intolerance**. Based on 100% free amino acids.

*Alfamino launch date early 2014

Important Notice: Breast milk is best for babies and provides ideal nutrition. Good maternal nutrition is important for preparation and maintenance of breastfeeding. Introducing partial bottle feeding could negatively affect breastfeeding and reversing a decision not to breastfeed is difficult. Professional advice should be followed on infant feeding. Infant formula should be prepared and used exactly as directed or it could pose a health hazard. The preparation requirements and cost of providing infant formula until 12 months of age should be considered before making a decision to formula feed.


References: 1. Alexander DD & Cabana MD. J Pediatr Gastroenterol Nutr 2010;50: 422-430. 2. Von Berg A et al. GINI Study Group. J Allergy Clin Immunol 2013; 111: 533-540. 3. Kemp AS, Hill DJ, Allen KJ, Anderson K, Davidson GP, Day AS, Heine RG, Peake JE, Prescott SL, Shugg AW, Sinn JK. Guidelines for the use of infant formulas to treat cows milk protein allergy: an Australian consensus panel opinion. MJA 2008;188(2): 109-112. 4. Vandemplas Y, Brueton M, Dupont C, Hill D, Isolauri E, Koletzko S, Oranje AP, Staiano A. Guidelines for the diagnosis and management of cow's milk protein allergy in infants. Arch Dis Child 2007;97:902-908. 5. Kemp A. Hypoallergenic formula prescribing practices in Australia. J Paed Child Health 2006;42:191-198.

Nestlé Australia Ltd. 1 Homebush Bay Drive, Rhodes NSW 2138. Nestlé Health Sciences 20-24 Howleys Road Notting Hill VIC 3168. ABN 77 000 011 318. ©Reg. Trademark of Société des Produits Nestlé S.A. Date of print: July 2013, The Arrol Group.

NUTRICIA ADVANCED ALLERGY MANAGEMENT

Nutricia leads the way in providing a comprehensive portfolio of products for Advanced Allergy Management in infants. Our products are scientifically researched for protection from and management of cows' milk protein allergy, and can help you make a difference to the lives of the infants, children and mothers you care for along their allergy journey.

We look forward to seeing you at our Nutricia Advanced Allergy Management stand at ASCIA 2013.



* For detailed guidelines on the management of cows' milk protein allergy, please refer to Kemp AS *et al.* MJA 2008; 188(2):109-112.

BREAST MILK IS BEST FOR BABIES: Professional advice should be followed before using an infant formula. Introducing partial bottle feeding could negatively affect breast feeding. Good maternal nutrition is important for breast feeding and reversing a decision not to breast feed may be difficult. Infant formula should be used as directed. Proper use of an infant formula is important to the health of the infant. Social and financial implications should be considered when selecting a method of feeding.

References: 1. Prescott SL *et al.* MJA 2005; 182(9):464-467. 2. Vanderplas Y *et al.* Arch Dis Child 2007; 91:902-908. 3. Verwimp JM *et al.* Eur J Clin Nutr. 1995; 49(Suppl 1):S39-S48. 4. ASCIA Cows' Milk (Dairy) Allergy <http://allergy.org.au/patients/food-allergy/cows-milk-dairy-allergy>, accessed 7 August 2012.

Karicare
Aptamil

FOR HEALTHCARE PROFESSIONALS ONLY
Nutricia Australia Pty Limited, Level 4, Building D, 12-24 Talavera Road, Macquarie Park, NSW 2113.
NBM1566-7/8/13-AU 11302.

NUTRICIA
neocate



WE'RE FIGHTING THE SAME FIGHT

**I HAVE A SEVERE
RESPIRATORY ALLERGY**

**I'M AN IMMUNOTHERAPY
RESEARCHER**

The biopharmaceutical company Stallergenes has been driving research and collaboration with the medical community for 50 years now and is at the forefront of allergen immunotherapy.

INNOVATION AT HAND
PATIENTS AT HEART



STALLERGENES



allergy and immunology foundation of australasia

WHO IS AIFA?

The Allergy and Immunology Foundation of Australia (AIFA) is an initiative of the Australasian Society of Clinical Immunology and Allergy (ASCI), the peak professional body for clinical immunology and allergy in Australasia.

AIFA is dedicated to funding education and research into disorders of the human immune system in Australia and New Zealand.

These disorders encompass **allergy**, including asthma, and other **immune diseases** such as primary immunodeficiency and autoimmune diseases.

WHY DO ALLERGY AND IMMUNE DISEASES MATTER?

Allergy and other immune diseases are amongst the fastest growing chronic and complex health conditions affecting children and adults in Australasia.

Allergic disease, and in particular food allergy, is rapidly increasing in young children.

Severe allergic reactions (anaphylaxis) and primary immunodeficiency diseases are potentially life threatening and cause significant impairment in day to day functioning.

WHAT NEEDS TO BE DONE?

More **research** is urgently needed into:

- Potential new treatments and cures for allergy, primary immunodeficiency and autoimmune diseases.
- Understanding why allergy and immune diseases are increasing so rapidly.
- Preventing allergy from occurring in the first place.
- Genetic testing and newborn screening for primary immunodeficiency.

High quality and far reaching **education** programs are urgently required to educate:

- Health professionals about early detection of allergy and immune diseases.
- The community about allergy and immune diseases.



www.allergyimmunology.org.au



allergy and immunology foundation of australasia

HOW CAN YOU HELP?

Every dollar counts.

By donating to AIFA you can help fund high quality education or research projects, selected by an expert panel, that have the greatest potential to help make a difference to 1 in 4 Australians and New Zealanders with allergy or other immune diseases.

Donations to AIFA can be made online at www.allergyimmunology.org.au or by cheque or EFT.

Donations of \$100 or more will be listed on the AIFA website (subject to donor permission) and donors of \$100,000 or more will be listed as founding sponsors of AIFA.

FAST FACTS

1. **Allergy and immune diseases (immunodeficiency and autoimmune diseases) are among the fastest growing chronic conditions in Australasia.**
2. Almost 20% of Australians and New Zealanders have an **allergic disease** and this prevalence is increasing.
3. Hospital admissions for **life threatening anaphylaxis** (severe allergic reactions) have increased 4 fold in the last 20 years.
4. **Food-induced anaphylaxis** has doubled in the last 10 years and 10% of infants now have an immediate food allergy.
5. **Immunodeficiency diseases** are serious, potentially life threatening conditions that are increasing in number and complexity.
6. Delay in diagnosis of **immunodeficiency disease** leads to poor health outcomes and premature death.
7. **Autoimmune diseases** affect 5% of Australians and New Zealanders and are more common than cancer or heart disease.
8. There are over 100 different **autoimmune diseases** that affect Australians and New Zealanders, and lead to significant disability.
9. There is a lack of public awareness about the impact and **appropriate management** of allergy and immune diseases.
10. **Access to care** is difficult, even in metropolitan areas, due to the high number of patients and low number of appropriately trained health care professionals, resulting in long waiting times to see a specialist.

Although this information is based on Australian data, it is expected that similar prevalence figures apply in New Zealand.

Reference: Allergy and Immune Diseases in Australia (AIDA) 2013 Report. www.allergy.org.au



www.allergyimmunology.org.au

Clinical Grand Rounds: Program

Wednesday 11 September 2013, 16.00-18.00

Perth Convention and Exhibition Centre, Bellevue Ballroom 2

Chairs: Prof Dominic Mallon, Prof Pete Smith

Each presentation has been allocated 8 minutes, comprising 4 minutes for a Powerpoint presentation (8 slides maximum) followed by 4 minutes for questions and discussion.

CGR 1	16.00-16.08	Russell Barker	AN AETIOLOGY FOR IGG4 RELATED DISEASE?
CGR 2	16.08-16.16	Dinusha Chandratilleke	A CULPRIT ANTIBODY SEIZES THE DAY
CGR 3	16.16-16.24	Jie Shen (Jason) Fok	A FATAL SWEET EXPERIENCE
CGR 4	16.24-16.32	Lara Ford	SWEET SYNDROME IN A 16-YEAR-OLD GIRL
CGR 5	16.32-16.40	Katie Frith	ONE IN A MILLION
CGR 6	16.40-16.48	Malanie Hettiarachchi	CLONAL PROLIFERATION OF T CELLS IN A YOUNG WOMAN WITH THE HYPEREOSINOPHILIC SYNDROME
CGR 7	16.48-16.56	Stephanie Hogarth	TRICHO-HEPATO-ENTERIC SYNDROME - THE FIRST CASE DESCRIBED IN AUSTRALIA
CGR 8	16.56-17.04	Jovanka King	USE OF ADJUNCTIVE SYSTEMIC CIDOFOVIR THERAPY IN A CHILD WITH SEVERE RECURRENT RESPIRATORY PAPILLOMATOSIS
CGR 9	17.04-17.12	Paul Mansfield	NOT SO HELPFUL T LYMPHOCYTES
CGR 10	17.12-17.20	Claire Nickolls	A CASE OF NEONATAL LIVER FAILURE: IRONING OUT THE DIAGNOSIS
CGR 11	17.20-17.28	Lawrence Ong	SECONDARY HYPOGAMMAGLOBULINAEMIA FOLLOWING LONG TERM ANTIPILEPTIC USE: AN UNCOMMON CAUSE OF SECONDARY IMMUNODEFICIENCY
CGR 12	17.28-17.36	Alberto Pinzon-Charry	INTRALESIONAL STEROIDS FOR THE TREATMENT OF CUTANEOUS GRANULOMAS IN ATAXIA TELANGIECTASIA
CGR 13	17.36-17.44	Jody Tansy	RITUXIMAB EFFECTIVE FOR LYMPHOCYTIC INTERSTITIAL PNEUMONITIS ASSOCIATED WITH SJOGREN'S SYNDROME: A CASE REPORT
CGR 14	17.44-17.52	Nicolas Urriola	A BRAF NEW WORLD
CGR 15	17.52-18.00	Andrew Whyte	LIMB-GIRDLE MUSCULAR DYSTROPHY: AN IMMUNOLOGICAL CONDITION?

Poster Abstracts: **Index** 2013

Note:

ASM = Annual Scientific Meeting 11-13 September 2013

IPU = Immunopathology Update 14 September

AIU = Allergy and Immunology Update 14 September

P1	(ASM)	Jodie Abramovitch	IGE REACTIVITY OF BLUE SWIMMER CRAB (PORTUNUS PELAGICUS) TROPOMYOSIN, POR P 1, AND OTHER ALLERGENS; CROSS-REACTIVITY WITH BLACK TIGER PRAWN AND EFFECTS OF HEATING
P2	(ASM, IPU)	Nayyar Ahmed	DISCOVERING THE EFFECTS OF OMEGA-3 FATTY ACIDS ON ALLERGY USING A HEK-BLUE CELL LINE
P3	(ASM, IPU)	Nayyar Ahmed	IDENTIFICATION AND CHARACTERIZATION OF A NOVEL CYTOKINE IL-13 ANTAGONIST FOR ALLERGY TREATMENT
P4	(ASM)	Janet Anderson	UPDATE ON THE UTILITY OF CHLORHEXIDINE SPECIFIC IGE TESTING IN THE INVESTIGATION OF PERIOPERATIVE ALLERGY
P5	(ASM)	Ulus Atasoy	RNA-BINDING PROTEIN HUR COORDINATELY REGULATES GATA-3, CD4+ TH2 AND TH17 CYTOKINE GENE EXPRESSION IN DOSE-DEPENDENT MANNER
P6	(ASM)	Sara Barnes	EVOLVING PRACTICE: X LINKED AGAMMAGLOBULINEMIA AND LUNG TRANSPLANTATION
P7	(ASM)	Sara Barnes	THE CHILD WITH A FOOD ALLERGY: CHALLENGES TO OUR FOOD SERVICE SYSTEM
P8	(ASM, AIU)	Melanie Batchelor	ANAPHYLAXIS DISCHARGE MANAGEMENT: IDENTIFYING GAPS AND REDUCING THE RISK
P9	(ASM, AIU)	Melanie Batchelor	FACTORS THAT INFLUENCE ADRENALINE AUTOINJECTOR NON-USAGE
P10	(ASM)	Andrew Broadfoot	EVALUATION OF CEFACTOR ELISA TESTING
P11	(ASM, IPU)	Shannon Brothers	RETROSPECTIVE REVIEW OF VARELISA ANTI-GLOMERULAR BASEMENT MEMBRANE ASSAY PERFORMANCE
P12	(ASM, IPU)	Christine Bundell	LOW LEVEL AUTOANTIBODIES ARE COMMON IN A GENERAL AUSTRALIAN POPULATION
P13	(ASM, IPU)	Christine Bundell	ANTINUCLEAR ANTIBODY TESTING IN A WESTERN AUSTRALIAN IMMUNOPATHOLOGY LABORATORY
P14	(ASM, AIU)	Pamela Burton	COMPARISON OF THREE SKIN PRICK TEST METHODS IN A PAEDIATRIC POPULATION
P15	(ASM, AIU)	Pamela Burton	CONSTRUCTION OF A GRASS POLLEN CALENDAR FOR THREE REGIONS IN GREATER SYDNEY
P16	(ASM, AIU)	Pamela Burton	INVESTIGATIONS AND FOLLOW UP OF PATIENTS WHO PRESENTED WITH LOCAL ANAESTHETIC REACTIONS
P17	(ASM, AIU)	Pamela Burton	NURSING STAFF KNOWLEDGE OF LATEX ALLERGY IN A TEACHING HOSPITAL
P18	(ASM)	Dianne Campbell	OUTCOME OF ORAL FOOD CHALLENGES TO BAKED MILK IN MILK ALLERGIC CHILDREN
P19	(ASM)	Gary Chew	GRANULOMATOUS DISEASE IN PRIMARY ANTIBODY DEFICIENCY: ANALYSIS FROM THE AUSTRALIAN NEW ZEALAND ANTIBODY DEFICIENCY ALLELE STUDY (ANZADA)
P20	(ASM)	Miriam Codarini	MEETING ALLERGY TRAINING NEEDS FOR PHYSICIANS WITH AN INNOVATIVE ONLINE COURSE
P21	(ASM)	Janet Davies	INCOMPLETE IgE CROSS-REACTIVITY BETWEEN POLLEN ALLERGEN FROM SUBTROPICAL AND TEMPERATE GRASSES IN PATIENTS FROM THE SUBTROPICS

Poster Abstracts: Index

P22	(ASM)	Janet Davies	REGIONAL AND SEASONAL VARIATION IN AIRBORNE GRASS POLLEN LEVELS BETWEEN CITIES OF AUSTRALIA AND NEW ZEALAND
P23	(ASM, AIU)	Maneka Deo	CANDLENUT ALLERGY IN NEW ZEALAND
P24	(ASM, AIU)	Suran Fernando	AN INTRIGUING CASE OF AMINE INTOLERANCE FOLLOWING A GENERALISED CUTANEOUS REACTION TO HONEY BEE VENOM
P25	(ASM)	Jie Shen (Jason) Fok	USE OF ICATIBANT IN ANGIOTENSIN-CONVERTING ENZYME (ACE) INHIBITOR-ASSOCIATED ANGIOEDEMA: OUR EXPERIENCE IN AUSTRALIA
P26	(ASM)	Alexander Headley	INVESTIGATING BASOPHIL NUMBER AND FUNCTION
P27	(ASM)	Peter Hsu	A PAEDIATRIC CASE SERIES OF SYSTEMIC CAPILLARY LEAK SYNDROME
P28	(ASM, IPU)	Miriam Hurst	OMEGA 5 GLIADIN POSITIVITY: NEW ZEALAND EXPERIENCE
P29	(ASM)	Sandip Kamath	DETECTION AND QUANTIFICATION OF THE AEROSOLIZED FOOD ALLERGEN TROPOMYOSIN - THE MAJOR SHELLFISH ALLERGEN
P30	(ASM)	Jovanka King	IGE-MEDIATED POVIDONE ALLERGY PRESENTING WITH ANAPHYLAXIS : A CAUSE OF MULTIPLE DRUG ALLERGY
P31	(IPU)	Elizabeth Klinken	MUCOSAL ASSOCIATED INVARIANT T (MAIT) CELL NUMBERS ARE REDUCED IN THE PERIPHERAL BLOOD OF RHEUMATOID ARTHRITIS PATIENTS
P32	(ASM, IPU)	Jamma Li	AQUAPORIN-4 TRANSFECTED CELLS IN THE DIAGNOSIS OF NEUROMYELITIS OPTICA
P33	(ASM)	Andreas Lopata	IN-VITRO ATOPY TESTING USING A NOVEL MODIFIED ELISA SYSTEM - THE FastCheck POC20
P34	(ASM)	Sam Mehr	THE FIRST 12 MONTHS OF FPIES SURVEILLANCE IN AUSTRALIA
P35	(ASM)	Fiona Moghaddas	AN ATYPICAL CLINICAL COURSE OF ISCHAEMIC BOWEL IN A PATIENT WITH HEREDITARY ANGIOEDEMA TREATED INITIALLY WITH ICATIBANT
P36	(ASM)	Fiona Moghaddas	OMALIZUMAB USE IN THE PREVENTION OF DELAYED REACTIONS POST VENOM IMMUNOTHERAPY: TWO CASES
P37	(ASM, AIU)	Philippe Moingeon	SCIENTIFIC RATIONALE SUPPORTING THE USE OF BOTH DERMATOPHAGOIDES PTERONYSSINUS AND D. FARINAE EXTRACTS FOR SPECIFIC IMMUNOTHERAPY
P38	(ASM, AIU)	Marry Moussa	SPRING: SYDNEY PROFESSIONAL IMMUNOLOGY NURSES GROUP
P39	(ASM, IPU)	Mahila Namasivayam	QUANTIFICATION OF HUMAN CYTOMEGALOVIRUS-SPECIFIC T-CELL RESPONSES IN PAEDIATRIC PATIENTS FOLLOWING HAEMATOPOIETIC STEM CELL TRANSPLANTATION
P40	(ASM, IPU)	Katherine Nicholls	COMPARATIVE ANALYSIS OF ENZYME LINKED IMMUNOSORBENT AND MULTIPLEX BEAD ARRAY ASSAYS FOR DETECTION OF ANTI-NEUTROPHIL CYTOPLASMIC ANTIBODIES WITH SPECIFICITY FOR MYELOPEROXIDASE AND PROTEINASE 3
P41	(ASM, AIU)	Emmanuel Nony	MASS SPECTROMETRIC ANALYSIS OF MAJOR ALLERGEN STABILITY WITHIN MIXTURES OF ALLERGENIC EXTRACTS INTENDED FOR IMMUNOTHERAPY
P42	(ASM, AIU)	Adeloisa Pajaro	RECURRENT POSTOPERATIVE PERICARDITIS IN A 39 YEAR OLD WOMAN TREATED WITH IMMUNOSUPPRESSIVE THERAPY AND INTERLEUKIN-1B RECEPTOR ANTAGONIST (ANAKINRA)
P43	(ASM)	Alberto Pinzon-Charry	ANTIMALARIAL TREATMENT RESTORES DENDRITIC CELL FUNCTION IN PATIENTS WITH MALARIA: IMPLICATIONS FOR VACCINATION
P44	(IPU)	Kerri Prain	LABORATORY TESTING FOR ANTI-N-METHYL-D-ASPARTATE RECEPTOR ENCEPHALITIS - THE HSSA-PATHOLOGY QUEENSLAND EXPERIENCE
P45	(ASM)	Kahn Preece	BACK TO BASICS


P46	(ASM, IPU)	Alex Quach	A HAPLOTYPE/DIPLTYPE ASSOCIATED WITH DELAYED TAC1 UPREGULATION AND INCREASED RISK OF COMMON VARIABLE IMMUNODEFICIENCY
P47			WITHDRAWN
P48	(ASM)	Katrina Randall	T CELL SUBSETS IN A MOUSE MODEL OF AUTOSOMAL RECESSIVE HYPER-IgE SYNDROME
P49	(AIU)	Susan Rochford	DOES CHANGE IN SYMPTOM SCORE REFLECT CHANGE IN LUNG FUNCTION FOLLOWING 6 MONTHS OF OMALIZUMAB TREATMENT?
P50	(ASM, AIU)	Sandra Salter	LONG TERM EFFECTIVENESS OF ASCIA ANAPHYLAXIS TRAINING FOR PHARMACISTS
P51	(ASM)	Michael Sharp	IMPACT OF HEATING ON ISOALLERGEN EXPRESSION IN BARRAMUNDI - DIFFERENTIAL IGE REACTIVITY IN ADULTS AND CHILDREN
P52	(AIU)	Farrukh Sheikh	FIRST STUDY OF PATTERN OF EPINEPHRINE AUTOINJECTOR PRESCRIPTIONS FOR ANAPHYLAXIS IN A LARGE TERTIARY CARE HOSPITAL IN SAUDI ARABIA
P53	(ASM)	Charlotte Slade	IMMUNOGENETICS CLINIC - A MULTIDISCIPLINARY APPROACH TO DIAGNOSIS AND MANAGEMENT
P54	(ASM)	Carling Southall	EFFECT OF CRYOPRESERVATION ON MONONUCLEAR CELL POPULATIONS: DETAILED EXAMINATION OF CD4+ T-CELL SUBSETS
P55	(ASM)	Ju Ann Tan	"ADULT FPIES": DOES IT EXIST?
P56	(ASM)	Ju Ann Tan	CHLORHEXIDINE ALLERGY: A SURPRISING PRESENTATION AND A CASE SERIES
P58	(ASM)	Grace Thompson	SKIN PRICK SENSITIVITY TO RAGWEED IN WESTERN AUSTRALIA
P59	(ASM)	Tilenka Thynne	SEVERE ACE INHIBITOR-ASSOCIATED ANGIOEDEMA IN THREE INDIGENOUS AUSTRALIANS
P60	(ASM)	Euan Tovey	MOST HOUSE DUST MITE AEROALLERGEN EXPOSURE OCCURS DURING THE DAY, NOT IN BED
P61	(ASM)	Sheryl Van Nunen	THE DEVELOPMENT OF TIARA (TICK-INDUCED ALLERGIES RESEARCH AND AWARENESS)
P62	(ASM)	Sheryl Van Nunen	A SURVEY OF CABIN AIR FILTERS IN POPULAR NEW CARS IN AUSTRALIA
P63	(ASM)	Sheryl Van Nunen	CLINICAL CORRELATES OF THE PRESENCE OF HLA B* 1502 IN VIETNAMESE PATIENTS WITH CARBAMAZEPINE-INDUCED STEVENS-JOHNSON SYNDROME (SJS), TOXIC EPIDERMAL NECROLYSIS (TEN) AND DRUG-INDUCED HYPERSENSITIVITY SYNDROME WITH RASH, EOSINOPHILIA AND SYSTEMIC SYMPTOMS (DRESS)
P64	(ASM)	Nirupama Varese	INTRACTABLE SHELLFISH ANAPHYLAXIS: SENSITISATION BY CROSS-REACTIVE SUBSTANCES IN A COMPLEMENTARY "IMMUNE STIMULANT" AND ACRYLIC NAILS
P65	(ASM, AIU)	Carol Whitehead	CASE DISCUSSION - MANAGING PEANUT ALLERGY RISK MINIMISATION AND ANXIETY, A PARENT AND SCHOOL PERSPECTIVE

Sponsors & Exhibitors

ASCIA 2013 Exhibition Floorplan

Please note:

- The Bellevue Ballroom 1 Pre-Function Lobby is the main entrance and the ASCIA 2013 registration desk will be located in this area.
- ASCIA 2013 presentations from Tuesday to Friday will be in Bellevue Ballroom 2.
- Catering and seating will be located in the ASCIA 2013 exhibition area.
- Posters will be displayed in the adjacent Bellevue Ballroom 2 Pre-Function foyer.
- Table top exhibition displays for the Saturday meetings are located in the foyer outside Riverview Room 4 and Meeting rooms 1-3 on level 2 of the Perth Convention and Exhibition Centre. These are not allocated stand numbers.
- The content of ASCIA 2013 is not influenced by its sponsors or exhibitors.



Exhibition Stand Allocations

Stand No.	Exhibitor	Wed-Fri	Sat
23,24	Abacus ALS	2	1
6	Allergend	1	1
12	Allergy & Anaphylaxis Australia	1	1
13	Allergy New Zealand	1	1
39,40	Alphapharm	2	1
14	Asthma Australia	1	
15	AusEE	1	1
36	AMSL/NZMS	1	1
20,21	Baxter	2	1
7	Bio-Strategy	1	
1,2	CSL Behring	2	1
	Diagnostic Solutions		1
29	Ego Pharmaceuticals	1	
	ESL Biosciences		1
3	GSK	1	
16	HAE Australasia	1	1
17	IDFA	1	1
18	IDFNZ	1	1
	In Vitro Technologies		1
33	Link	1	1
31	Meda	1	
11	MedicAlert Foundation	1	1
9,10	MSD	2	
30	Neilmed	1	
27,28	Nestlé Nutrition	2	1
37,38	Novartis	2	
4	Nutricia Baby	1	
5	Nutricia Advanced Medical	1	
8	Octapharma	1	
34,35	Shire Australia	1	
25,26	Stallergenes	2	1
22	Takeda	1	
19	TAMS	1	1
32	ViroPharma	1	1

Sponsor & Exhibitor Directory



www.abacus-als.com

Abacus ALS will showcase a number of new advances in allergy, asthma and autoimmunity. Kerstin Wall (Scientific Advisor, Thermo Fisher Scientific) will be on our booth to discuss the new and updated allergen components including those to wheat, walnut, cashew, hazelnut, grass and birch.

Molecular Allergology can help with risk assessment of the allergy, explain symptoms due to cross-reactivity and help in identifying patients suitable for SIT treatment while supporting the doctor in patient management.

The gastrointestinal disease test menu on the Phadia® platforms has expanded to include EliA ASCA in addition to the fully automated Calprotectin stool test for diagnosing sufferers of IBD. These new tests complement our existing range of EliA assays including our leading assays for diagnosing coeliac disease (Celikey tTG and DGP).

Abacus ALS will provide visitors to our booth a complimentary copy of the most up-to-date allergy and autoimmunity resources on a USB stick.



www.abbottnutrition.com.au

Abbott Nutrition, a division of Abbott Australasia is committed to advancing patient care by developing innovative solutions in nutritional products. Our leading-edge science is behind some of the world's most trusted names in medical nutrition, including EleCare®, which is a nutritionally complete amino acid based formula with 1/3 of fat as Medium Chain Triglycerides (MCTs), to aid fat absorption. This product has been specially formulated for infants and children who have multiple food allergies, including cow's milk protein allergy. In addition, EleCare Unflavoured and EleCare Vanilla are also indicated for the treatment of Eosinophilic Oesophagitis. EleCare® is PBS listed and is available in three variants, EleCare Unflavoured, EleCare Unflavoured with LCP and EleCare Vanilla.



THE ULTIMATE DUST MITE PROTECTIVE BEDDING

www.allergend.com.au

AllergEnd Plus is the Ultimate dust mite protective bedding. Made in Melbourne, our AllergEnd Plus bedding range has established us as market leaders. Our fully zippered pillow, mattress and quilt encasings act as a complete barrier to dust mites and their associated allergens. It is a breakthrough in dust mite protection. The AllergEnd Plus fabric is Oeko-Tex Standard 100 certified chemical free cotton that is breathable and luxuriously comfortable to sleep on.

AllergEnd Plus can be purchased online at www.allergend.com.au, via phone on Free Call 1800 656 484 or in person direct from our factory at 132a Cotham Road, Kew Victoria 3101.



Allergy & Anaphylaxis
Australia

Your trusted charity for allergy support

www.allergyfacts.org.au

Allergy & Anaphylaxis Australia (A&AA) is a national, non-profit community support organisation established in 1993 to support and assist those affected by allergy and anaphylaxis.

Allergy & Anaphylaxis Australia is dedicated to assisting individuals and their carers in the management of allergic disease including the risk of anaphylaxis. Our aim is to improve the quality of life of those affected by allergy whilst minimising risk to their health and well-being. The organisation advocates for people living with allergies when communicating with government, health and teaching professionals, food industry and the broader community.

Allergy & Anaphylaxis Australia strives to raise awareness of allergy in the Australian community and provides evidence-based information, resources and services to support those with allergy and those who live with the risk of anaphylaxis.

For more information on allergy and anaphylaxis see our website or call 1300 728 000.



www.allergy.org.nz

Allergy New Zealand is the national patient support organisation in New Zealand. With the support of a Medical Panel (all members of ASCIA) we work to raise awareness, provide evidence-based information and education on all allergies, and

support through a national volunteer network to families with children with food allergy. Our quarterly magazine, Allergy Today, is distributed to over 5,000 health professionals. We also represent the interests of the allergic population through submissions and participation in working groups; and are involved in research into the burden of food allergy in New Zealand. See our website for more information: www.allergy.org.nz



www.alphapharm.com.au

Alphapharm is Australia's leading supplier by volume of prescription medicines to the Pharmaceutical Benefits Scheme (PBS). Alphapharm's EpiPen® is the number one prescribed epinephrine auto-injector in Australia. Alphapharm supplies EpiPen® to Australians via the PBS, with two pens available on each prescription. Alphapharm is helping to improve the awareness of anaphylaxis in the community and improve access to epinephrine auto-injectors through the 'Back to School' information campaign. Alphapharm also sponsors Allergy & Anaphylaxis Australia to provide independent education for schools to create awareness and preparedness to manage anaphylaxis, as well as helping schools to recognise the need to have epinephrine auto-injectors and expertise to use them, in the event a person experiences anaphylaxis at school.



asthmaaustralia.org.au

Cure. Care. Community. Asthma Australia and Asthma Foundations – the nations' leading lung health charities

Together we seek a cure for asthma. Together we strive to improve the quality of life for people with asthma by providing accessible, affordable and evidence based services. Together to achieve our vision we raise funds ethically.

For over 50 years Asthma Australia and Asthma Foundations have been the leaders in asthma in health care and research. Asthma Australia and member Foundations deliver high quality support to people with asthma and their carers. As one of the country's largest and most respected respiratory organisations, with offices and staff in every State and Territory of Australia, Asthma Australia delivers evidence-based preventative health strategies to over 200,000 people every year. We offer support, training, and resources to the primary health care sector and when treatment is required we ensure patients and their carers have the knowledge,

information and power to be actively engaged in the decision making process. We fund vital basic science and population health research contributing to national and international understandings of asthma and how best to manage the disease.

1800 ASTHMA – asthmaustralia.org.au



www.ausee.org

ausEE Inc. is an Australian charity and non-profit organisation dedicated to providing support and information to anyone diagnosed with or caring for someone with an Eosinophilic Gastrointestinal Disorder (EGID) including Eosinophilic oEsophagitis (EoE).

ausEE is committed to raising public awareness and supporting the medical community for further research into eosinophilic disorders in Australia. We have an active facebook group providing valuable support to parents and caregivers.

Please visit our website to order your free patient resources including children's picture books on EoE, EGID medical brochures and patient information folders.



Australia: www.amsl.com.au

New Zealand: www.nzms.co.nz

At Australasian Medical and Scientific Ltd (AMSL) and New Zealand Medical and Scientific Ltd (NZMS) we deliver leading allergy solutions to allergists, dermatologists and other medical practitioners throughout Australia and New Zealand.

Our range includes Sub Lingual, Subcutaneous and Tablet Immunotherapy Vaccines; Skin Prick Test allergens; ready to use and open type Patch Test Systems; intradermal allergen tests for penicillin, amoxicillin and clavulanic acid; RhinoLight for treatment of allergic rhinitis; lancets and accessories.

Our range includes leading brands such as ALK Abello, SmartPractice, Lincoln Diagnostics and Diater. We pride ourselves on our experience and expertise in the field of allergy diagnosis and immunotherapy as well as our reliable and excellent service.

Sponsor & Exhibitor Directory

Baxter

www.baxterhealthcare.com.au

Baxter Healthcare develops, manufactures and markets products that save and sustain the lives of people with haemophilia, immune disorders, infectious diseases, kidney disease, trauma, and other chronic and acute medical conditions. As a global, diversified healthcare company, Baxter applies a unique combination of expertise in medical devices, pharmaceuticals and biotechnology to create products that advance patient care worldwide.



bio-strategy

delivering technology

www.bio-strategy.com.au

Bio-Strategy is a team of highly qualified people, throughout Australia and New Zealand, who share a passion for Science.

Representing world leading suppliers, Bio-Strategy brings our customers a complete range of solutions, from basic laboratory instrumentation through to advanced technology, covering applications in the Research, Healthcare, Biotechnology and Industrial Markets.

Our focus and commitment to our customers and suppliers, is key to Bio-Strategy's excellence and success.

CSL Behring

www.cslbehring.com.au

CSL has been the chosen national plasma fractionator of Australia since 1953, and New Zealand since 1963. Today CSL Behring works with Australian Governments, the Australian Red Cross Blood Service and the New Zealand Blood Service to deliver a world class and broad range of plasma-derived therapies specifically designed to meet the needs of healthcare professionals and patients in both these countries.

CSL Behring, through its research and development program, is committed to ensuring continued world class standards of quality, product yields, patient convenience and manufacturing efficiency in our broad portfolio of plasma-derived therapies. An example of this commitment is the use of modern manufacturing technologies for our products, such as large scale chromatography and the inclusion of at least two dedicated and complementary pathogen reduction steps in the manufacturing process of each product for Australia and New Zealand.

Diagnostic Solutions

www.diagnosticsolutions.com.au

Diagnostic Solutions is a leading distributor of high quality, innovative automated systems for autoimmune diagnostic testing across Australia and New Zealand.

The Image Navigator® from Immuno Concepts is the most advanced automated IFA system today. With true sample traceability, fast positive / negative screening combined with interfacing to the CARIS™/DSR™ Systems using the DEESSE software the system can provide workflow streamlining capability for your laboratory.

Please visit our display to see a demonstration of the Image Navigator® and talk to us about how we can assist your laboratory with your Autoimmune testing needs.

Australia: 1300 788 003 New Zealand: 0800 448 018



www.egopharm.com

Ego Pharmaceuticals is an Australian family owned and operated company who for more than 50 years have specialised in the manufacture of quality skincare products such as market leaders 'QV', 'Sunsense', 'Pinetarsol', 'DermAid' and 'Moov'. The QV range of gentle moisturisers and cleansers has been scientifically formulated for those who suffer from dry or sensitive skin conditions. The entire QV range is free from colour, fragrance, propylene glycol, lanolin and its derivatives making it ideal for the most sensitive skin types.



www.eslbioscience.com

ESL Biosciences supplies high quality, automated in-vitro diagnostic instruments and reagents and provides full training in their use throughout Australasia.

With over 25 years of experience in the niche field of autoimmunity we offer a comprehensive range of products from Euroimmun, a world-leader in autoimmune diagnostics. Assays include (but are not limited to) those for Rheumatology, Autoimmune Hepatitis, PBC and Vasculitis. Others include test kits

for the determination of Gluten sensitivity, antibody test kits for Autoimmune Mediated Diabetes markers and Autoantibodies in Paraneoplastic Neurological Syndromes (PNS).

ESL Biosciences also presents a range of automated systems to the laboratory.



www.gsk.com.au

GlaxoSmithKline is a global research-based pharmaceutical and healthcare company with a mission to improve the quality of human life by enabling people to do more, feel better and live longer. In Australia we have improved people's wellbeing by delivering the highest quality medicines, vaccines and over-the-counter healthcare products since 1886. We provide about 1700 skilled jobs across the country, working with researchers and doctors to discover new ways of treating and preventing disease. In 2012 we invested \$54 million in local research and development, and supplied \$521 million to Australia's pharmaceutical and medicinal exports.



www.haeaustralasia.org.au

HAE Australasia is a not for profit organization, founded by HAE patients and caregivers and is dedicated to providing a support network for those with Hereditary Angioedema.

HAE Australasia is enhancing the support and quality of life for HAE patients, providing education to patients, carers and health care providers and is raising awareness of HAE in the medical and general community, assisting research organizations with their studies into causes, prevention and treatment of HAE. HAE Australasia is also looking at ways to make treatment and medications more accessible for patients across Australia and New Zealand.



www.idfa.org.au

Immune Deficiencies Foundation of Australia (IDFA) is the patient organisation for people affected by Primary Immune Deficiencies in Australia. IDFA provides education, information, advocacy, communication and support to members.

IDFA is governed by a Board of Directors which includes two leading Australian Immunologists (Paediatric and Adult). IDFA is a member of IPOPI (International Patient Organisation for Primary Immunodeficiencies) and has representation on the IPOPI Board. IDFA welcomes membership from Immunologists and other Health Professionals.

For further information, email christine.jeffery@idfa.org.au, call 0409 945 114 or visit our website.



www.idfnz.org.nz

Immune Deficiencies Foundation of New Zealand (IDFNZ) is a registered charity which has served patients of all ages with diagnosed Primary Immune Deficiency (PID) disorders since 1989.

IDFNZ offers individual patient support, education, advocacy and information. IDFNZ also sponsors medical and scientific research, and promotes awareness of PID to the general public and health professionals including visiting speaker and awareness programmes.

IDFNZ is governed by a volunteer Board which includes representatives from our medical advisory panel, comprising of leading medical professionals specialising in PID disorders. IDFNZ is a foundation member of the International Patient Organisation for Primary Immune Deficiencies (IPOPI).



www.invitro.com.au

In Vitro Technologies specialises in the sale and support of scientific, diagnostic, medical and related products in Australian and New Zealand. The Diagnostics Division represents leading global niche market companies in biochemistry, autoimmunity, immunology, haematology, microbiology, and point of care.

In Vitro Technologies marketing partners include Immco Diagnostics. Immco develops and distributes autoimmune disease products to labs worldwide, offering a comprehensive selection of autoimmune diagnostics under the leading brands: ImmuGlo™, ImmuLisa™, and ImmuBlot™. Immco assay development led to the first immunofluorescence assay for diagnosing coeliac disease. Immco is continually expanding their product offering, providing the total solution in autoimmunity. Ph: 1 300 552 003

Sponsor & Exhibitor Directory



www.linkhealthcare.com.au

LINK Healthcare is a privately owned Australian-based specialist pharmaceutical and medical technologies business. LINK's mission is to strive for excellence in the marketing of a vitally important and unique range of specialists products that enhance the well-being of people throughout the regions of Australia, New Zealand.

LINK provides exceptional sales and marketing infrastructure and is partnered with major pharmaceutical & medical device companies from around the world, allowing the company to offer a unique and substantial portfolio.

LINK Pharma has an extensive range of prescription pharmaceuticals in essential therapeutic areas including Allergy, Anaphylaxis, Analgesia/Anesthesia, Anti-infective, Cardiology, Endocrinology, ENT, Gastroenterology, Intensive care, Metabolic disease, Neurology, Oncology, Orphan Drugs, Palliative care, Psychiatry, Radiography, Transplantation and Toxicology.



www.medapharma.com

Meda is an international specialty pharmaceutical company with its own sales organisations in over 50 countries and operations expanding in growth markets. Meda has total coverage of about 75% of the global pharmaceutical market.

Meda's products are available in more than 120 countries, and Meda is about the 50th largest pharmaceutical company in the world by sales.

Meda's well-diversified product portfolio is divided into three segments: Specialty Products, Branded Generics and OTC. Meda focuses mainly on five key therapy areas: respiratory, dermatology, cardiology, CNS, pain and inflammation.



www.medicalert.org.au

Australia Medic Alert Foundation is a registered non-profit membership-based organisation that provides a trusted 24/7 personal emergency medical information service for people with medical conditions including allergies, special medications and/or advanced wishes.

Members wear a bracelet or necklace with a genuine MedicAlert emblem personally engraved with their vital medical information, membership number and 24/7 hotline number. This number is available for emergency services and healthcare professionals to

call to access the members' important information held on file in an emergency.

To request membership forms or other resources, you can visit our Healthcare Professionals page on our website or call FREECALL 1800 88 22 22.



www.msd-australia.com.au

Today's MSD is a global healthcare leader working to help the world be well. MSD is a tradename of Merck & Co., Inc., with headquarters in Whitehouse Station, N.J., U.S.A. Through our prescription medicines, vaccines, biologic therapies, and consumer care and animal health products, we work with customers and operate in more than 140 countries to deliver innovative health solutions. We also demonstrate our commitment to increasing access to healthcare through far-reaching policies, programs and partnerships. MSD. Be well. For more information, visit www.msd-australia.com.au



www.nationalasthma.org.au

The National Asthma Council Australia (NAC) was formed in the late 1980s, to lead a national effort to combat the alarming number of deaths from asthma in the 1980s. This figure has since fallen dramatically with improved management of asthma by health professionals, patients and their carers.

The NAC continues to develop asthma management campaigns and information that helps people with asthma lead healthy, active lives. It also conducts a national education program in rural, remote and urban Australia for GPs, primary health care nurses, pharmacists, Aboriginal health workers and asthma educators to help them provide better care for people with asthma.



www.neilmed.com

NeilMed Pharmaceuticals, manufacturers of allergy & sinus relief products. NeilMed's Sinus Rinse[®] Kit, a soothing saline nasal irrigation system with 60 packets of preservative free, isotonic, pH balanced mixture, irrigation bottle, custom designed cap. Highly effective for rhinosinusitis, allergies, and most beneficial for post FESS patients. NeilMed's NasaFlo[®], free flowing gravity method to nasal irrigation. NeilMed's NasoGel[®], a soothing saline gel

for prolonged moisturization of dry nasal passages. NeilMed's NasaMist[®], buffered, preservative free nasal spray, isotonic and hypertonic available. NasaDrops Ampoules with Aspirators Saline ampoules for stuffy, congested or dry noses for babies, children & adults. www.neilmed.com. Tel: 1300 652 148



Good Food, Good Life

www.nestle-hcp.com.au

www.nestlehealthscience.com.au

Nestlé is the world's leading Nutrition, Health and Wellness company. Through integrating scientific and research expertise, Nestlé Nutrition aims to pioneer the development and application of evolving science to help children develop to their full potential plus create a new role for nutrition in disease prevention and management. Nestlé Health Science & Nestlé Nutrition offer both high quality nutrition for children in the crucial first years of life & nutritional solutions for people with specific dietary needs related to illnesses, disease states or the special challenges of different life stages.

As a long time partner of ASCIA please come and visit us during this year's meeting to find out more about our product range.



www.novartis.com.au

Novartis is a world leader in the research, development and supply of medicines to prevent and cure diseases, ease suffering and enhance quality of life.

Headquartered in Basel, Switzerland, we employ approximately 100,000 people worldwide and operate in over 140 countries.

Novartis offers a wide range of healthcare products through our Pharmaceuticals, Vaccines and Diagnostics, Sandoz and Consumer Health Divisions. Our medicines treat some of the most serious conditions confronting healthcare professionals and their patients in the areas of cardiovascular disease, oncology, immunology, infectious diseases and ophthalmics.

In Australia Novartis employs more than 900 people, and invests over AUD \$30 million annually in local research.



www.nutricia4professionals.com.au

Nutricia leads the way through years of experience in providing a comprehensive portfolio for Advanced Allergy Management. Our products are scientifically researched for protection from and management of cows' milk protein allergy.

We look forward to discussing with you how Nutricia's expertise and comprehensive allergy portfolio can assist you. By offering an unmatched superior nutritional profile, Nutricia can help you make a difference to the lives of the infants, children and mothers you care for along their allergy journey.

Visit the Nutricia Advanced Allergy Management stand 4 and 5 to find out more.



www.octapharma.com.au

Octapharma specialises in the development and production of human proteins derived from plasma and recombinant technologies. Using cutting-edge purification and viral inactivation techniques we live by our mission of "for the safe and optimal use of human proteins."

We provide life saving therapies to our patients worldwide in the treatment of multifarious diseases in Haematology, Immunotherapy, Intensive Care and Emergency Medicine.

Octapharma operates and manufactures products to the standards of quality and safety required by regulatory authorities globally. Please contact Octapharma Australia for more information.



www.pathwest.com.au

PathWest Laboratory Medicine WA is committed to providing excellence and innovation in pathology testing, teaching and research, positively contributing to the health and wellbeing of the community. We have a proud service record and as Western Australia's leading referral pathology laboratory we respond to the needs of virtually every medical practitioner in the State.

Our active teaching, clinical research and pathology development programs assist not only in enhancing diagnostic accuracy but also in improving the understanding of disease processes and of clinical care.

Sponsor & Exhibitor Directory



www.shireaustralia.com.au

As one of the leading specialty biopharmaceutical companies, Shire focuses on a single purpose: to enable people with life-altering conditions to lead better lives. Shire's Rare Diseases Business Unit focuses on research, developing and providing treatments that enhance the quality of life of patients suffering from rare diseases. Established in 2008, Shire Australia offers products in Fabry and Gaucher Diseases and Hereditary Angioedema.

Shire also provides products for Hyperphosphataemia in CKD5D, Essential Thrombocythaemia and mild to moderate active Ulcerative Colitis. Address: Level 6, 123 Epping Road, North Ryde, NSW, 2113. Phone: +61280194400; www.shireaustralia.com.au; Customer Services: 1800012612 or enquiriesaustralia@shire.com



www.stallergenes.com

For over half a century Stallergenes has been a leader and pioneer in allergen immunotherapy. With a strong commitment to research and development, Stallergenes dedicates close to 20% of its turnover each year to the development of innovative and evidence-based treatments.

Locally, Stallergenes Australia is dedicated to supporting the Australasian allergist community in addressing the

significant unmet need of patients with moderate to severe allergic respiratory disease. Our investment to this cause is evident through the consistent sponsorship, support and grants we provide along with delivering the only TGA and Medsafe registered AIT treatments on the ANZ market.



www.takedaaustralia.com.au

Takeda is a research-based global pharmaceutical company. It is the largest pharmaceutical company in Japan and an industry leader. Takeda is committed to striving towards better health for patients worldwide through leading innovation in medicine. Takeda's in-house ethical drugs are marketed in around 90 countries worldwide and focus on gastrointestinal, respiratory, oncology, central nervous system, cardiovascular and diabetes. Takeda Australia aims to launch numerous products from the impressive Takeda pipeline, supplemented by additional in-licensed products, in the next few years.



THE AUSTRALASIAN MASTOCYTOSIS SOCIETY

www.mastocytosis.com.au/

Education, Advocacy, Support, Research

The Australasian Mastocytosis Society (TAMS), formed in 2011 is working to;

- Provide a network of support for patients living with Mastocytosis or a Mast Cell Activation Disorder (MCAD) and their carers
- Connect patients to medical practitioners and specialists with knowledge of Mastocytosis and MCAD
- Link together with similar associations worldwide to collectively gather research data, share resources and knowledge in the hope of greater understanding, treatment practices, medications and overall improved health outcomes for those living with Mastocytosis or MCAD.



www.viropharma.com

ViroPharma is an international biopharmaceutical company committed to developing and commercialising innovative products that address unmet medical needs.

ViroPharma focuses on providing products to healthcare professionals that support patients with serious conditions, including disease caused by C1 esterase inhibitor deficiency.

ViroPharma is dedicated to transforming the promise of biotechnology into therapies that have the power to restore health and save lives.

For further information, please contact ViroPharma Customer Service on:

Toll-free telephone: 1800 767 232

Email: au.customerservice@viropharma.com

The advertising space for ASCIA 2014 (see opposite page) has been supported by

CSL Behring

a Diamond Sponsor of ASCIA in 2013 and a Founding Sponsor of AIFA.

ASCIA 2014

25th annual scientific meeting
of the Australasian Society of Clinical
Immunology and Allergy (ASCIA)

Wednesday 10th to Saturday 13th September 2014
Melbourne Convention and Exhibition Centre
Victoria Australia

Registration and abstract submission will be available
by late April 2014 at www.ascia2014.com.au

ASCIA is the peak professional body of
clinical immunology and allergy in
Australia and New Zealand

ascia

australasian society of clinical immunology and allergy inc.

24 years of ASCIA Annual Scientific Meetings 1990 – 2013



- 1990 1st ASCIA ASM – Melbourne VIC (Hilton on the Park, April 29 - May 1)
- 1991 2nd ASCIA ASM – Perth, WA (Burswood Hotel, December 1-3)
- 1992 3rd ASCIA ASM – Cairns, QLD (Hilton Hotel, September 13-15)
- 1993 4th ASCIA ASM – Sydney, NSW (Darling Harbour, April 29 – May 1)
- 1994 5th ASCIA ASM – Canberra, ACT (Lakeside Hotel, December 2-5)
- 1995 6th ASCIA ASM – Sydney, NSW (Regent Hotel, October 30-November 3) with TPAIS
- 1996 7th ASCIA ASM – Adelaide, SA (Hyatt Hotel, December 5-7)
- 1997 8th ASCIA ASM – Wellington, NZ (Convention Centre, April 5-8) held with TSANZ
- 1998 9th ASCIA ASM – Brisbane, QLD (Sheraton Hotel, August 28-30)
- 1999 10th ASCIA ASM – Uluru, NT (Ayers Rock Resort, September 24-27)
- 2000 11th ASCIA ASM – Sydney, NSW (Convention Centre, October 15-20)
(held as part of the 17th World Allergy Congress)
- 2001 12th ASCIA ASM – Perth, WA (Sheraton Hotel, September 28-30)
- 2002 13th ASCIA ASM – Adelaide, SA (Hilton Hotel, September 27-29)
- 2003 14th ASCIA ASM – Melbourne, VIC (Sheraton Southgate Hotel, September 10-12)
- 2004 15th ASCIA ASM - Gold Coast, QLD (Marriott Hotel, September 8-10)
- 2005 16th ASCIA ASM – Queenstown, NZ (Millennium Hotel, August 31 - September 2)
- 2006 17th ASCIA ASM – Sydney, NSW (Manly Pacific Hotel, September 7-9)
- 2007 18th ASCIA ASM – Fremantle, WA (Esplanade Hotel, November 14-16)
- 2008 19th ASCIA ASM - Melbourne (Park Hyatt Hotel, November 12-14)
- 2009 20th ASCIA ASM – Adelaide, SA (Adelaide Convention Centre, September 16-18)
- 2010 21st ASCIA ASM – Gold Coast, QLD (Gold Coast Convention & Exhibition Centre, September 1-4)
- 2011 22nd ASCIA ASM – Sydney, NSW (Sydney Convention & Exhibition Centre, Darling Harbour, September 6-10)
- 2012 23rd ASCIA ASM – Wellington, New Zealand (Wellington Town Hall, September 5-7)
- 2013 24th ASCIA ASM – Perth, Western Australia (Perth Convention and Exhibition Centre, September 10-14)